PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Aurisco – 04/02/2025
Biopharma Group – 19th March 2025

LeapFrog acquires majority stake in Ascent Meditech

The investment will tap into the rapidly growing $100 billion Indian healthcare market

LeapFrog Investments (“LeapFrog”), the leading investor in companies that deliver healthcare and financial services for emerging consumers, have acquired a majority stake in Ascent Meditech (“Ascent”).

Ascent Meditech is the leading Indian medical products company and distributor of niche consumer healthcare products, with a focus on orthopaedics, pain and wound care. It is behind the market-leading Flamingo brand.

The company’s products are currently sold to seven million customers, with a focus on providing high quality and competitively priced orthopaedic products.

Over 80% of Ascent products are purchased for treatment for orthopaedic disorders, which affect over 200 million people in India.

The share of India’s population over the age of 60 is projected to increase from 8% today to 19% by 2050. By the end of the century, the elderly will constitute nearly 34 percent of the total population in the country.

Elderly populations tend to have a higher prevalence of orthopaedic ailments, preferring less invasive solutions to surgery.

The company sold 15 million products to Indians in 2017 via 150,000 retail pharmacy points across 12 Indian states.

The company currently exports to over 40 countries across Asia, Africa and the Middle East. Specifically tailored to offer value for money, Ascent’s products have achieved ISO and CE standards, along with FDA approvals.

LeapFrog will leverage its deep expertise in healthcare and emerging consumer insights to support Ascent’s growth plans and will create additional value through continuing to strengthen the Flamingo brand, utilising LeapFrog-generated consumer insights to develop additional consumer-focused products, and expand Ascent’s presence in sub-Saharan Africa and Southeast Asia by leveraging LeapFrog’s network in these geographies.

This investment builds on LeapFrog’s decade of experience in providing health insurance to emerging consumers, and track record in the Indian market.

 

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40
Eppendorf – 18.03.2025